MARKET

BLPH

BLPH

Bellerophon
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.06
-0.25
-2.03%
After Hours: 12.06 0 0.00% 16:00 08/11 EDT
OPEN
12.70
PREV CLOSE
12.31
HIGH
12.74
LOW
11.99
VOLUME
88.00K
TURNOVER
--
52 WEEK HIGH
26.00
52 WEEK LOW
3.186
MARKET CAP
114.54M
P/E (TTM)
-3.5291
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BLPH stock price target is 31.67 with a high estimate of 35.00 and a low estimate of 30.00.

EPS

BLPH News

More
Bellerophon Therapeutics EPS beats by $0.21
Bellerophon Therapeutics (NASDAQ:BLPH): Q2 GAAP EPS of -$0.51 beats by $0.21. Cash and cash equivalents of $59.3M. Press Release
seekingalpha · 6d ago
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2020 Financial Results
WARREN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today provide
GlobeNewswire · 6d ago
Bellerophon Therapeutics Announces Publication Of Cohort 1 Of iNO-PH Phase 2/3 Study In The CHEST Journal, Participation In Webinar To Discuss Clinical Results
Benzinga · 07/15 12:31
Bellerophon Therapeutics Announces Publication of Cohort 1 of iNO-PF Phase 2/3 Study in the CHEST Journal and Participation in Webinar to Discuss Clinical Results
Patients Treated with INOpulse® Demonstrated Improved Physical Activity Compared to Placebo Live Webinar with Study Investigators on Thursday, July 16th, from 4:00-5:00 pm EDT.
GlobeNewswire · 07/15 12:30
Bellerophon advances late-stage study of INOpulse for COVID-19
Bellerophon Therapeutics (BLPH +4.8%) announces that the first patient has initiated treatment in Phase 3 study of INOpulse inhaled nitric oxide therapy fo
seekingalpha · 07/13 21:54
Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19
WARREN, N.J., July 13, 2020 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and.
GlobeNewswire · 07/13 12:30
Bellerophon Therapeutics Added to Russell 3000® and Microcap® Indexes
GlobeNewswire · 06/29 13:00
Russell adds lineup of healthcare firms to key indexes
Seeking Alpha - Article · 06/29 12:25

Industry

Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-0.89%

Hot Stocks

Symbol
Price
%Change

About BLPH

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. The Company's INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. INOpulse is designed to be compatible with many long-term oxygen therapy (LTOT) systems via nasal cannula delivery.
More

Webull offers kinds of Bellerophon Therapeutics Inc stock information, including NASDAQ:BLPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLPH stock methods without spending real money on the virtual paper trading platform.